🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Xi’an
Clinical trial register · China

Clinical Trials in Xi’an, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Xi'an 45 Xi’an 5 Beijing 3 Chongqing 3 Shenyang 2
Narrow the registerReset
Recruitment status
Phase
Site location
Xi'an45 Xi’an5 Beijing3 Chongqing3 Shenyang2
All 20 locations
Target enrolment
to

Trials with a site in Xi’an

49 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma
NCT07752394Head & Neck Cancer
Tang-Du Hospital
Phase 2
15
Xi’an
2026-08-23
Not yet open
A National Multicenter Study of Etrasimod for the Treatment of Patients With Active UC
NCT07705126Ulcerative Colitis (UC)
Tang-Du Hospital
Observational
500
Xi’an
2026-07-15
Not yet open
Neoadjuvant Short-Course Radiotherapy Plus Tislelizumab and Chemotherapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT07678580Esophageal Squamous Cell Carcinoma (ESCC)
Tang-Du Hospital
Phase 2
50
Xi'an
2026-07-10
Recruiting
Multi-Field-Strength MRI Brain Atlas Construction in Healthy Chinese Population
NCT07786233Healthy Adult Brain Imaging
Tang-Du Hospital
Not applicable
500
Xi'an
2026-07-01
By invitation
Predictive Efficacy of Fecal Calprotectin Assay by Magnetic Particle Chemiluminescence for Mucosal Healing in Moderate-to-Severe Ulcerative Colitis Patients Undergoing Initial Biologic Therapy(PRECAL)
NCT07721441Ulcerative Colitis (UC)
Tang-Du Hospital
Observational
200
Beijing, Chongqing, Shenzhen, Wuhan, Nanjing, Shengyang, Qingdao, Xi’an
2026-06-18
Not yet open
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
NCT07699770Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain
Tang-Du Hospital
Phase 4
110
Beijing, Chongqing, Harbin, Hohhot, Changchun, Shenyang, Xi'an, Ürümqi
2026-06-15
Not yet open
Bristol Stool Scale-Based Care Pathway for Enteral Nutrition-Associated Diarrhea in Critically Ill Patients
NCT07683364Critical Illness, Diarrhea
Tang-Du Hospital
Not applicable
60
Xi'an
2026-06-15
Not yet open
Retlirafusp Alfa Plus Chemotherapy as Neoadjuvant Therapy for Thoracic ESCC
NCT07618910Esophageal Squamous Cell Carcinoma
Tang-Du Hospital
Phase 2
33
Xi'an
2026-05-30
Recruiting
Serplulimab Monotherapy in Elderly Patients With NSCLC and PD-L1 TPS ≥ 50%
NCT07596121NSCLC (Non-small Cell Lung Cancer)
Tang-Du Hospital
Phase 2
60
Xi'an
2026-05-13
Recruiting
Time-of-Day of Immunotherapy Infusion in Neoadjuvant Immunochemotherapy for Thoracic ESCC
NCT07452601Esophageal Squamous Cell Carcinoma
Tang-Du Hospital
Phase 2
90
Xi'an
2026-05-05
Not yet open
An Open-Label, Dose-Escalation Study on the Safety, Tolerability and Preliminary Efficacy for Preventing SAP by Intravenous Pump-Delivered Propranolol in Patients With ICH
NCT07528235Intracerebral Hemorrhage, Stroke-Associated Pneumonia (SAP)
Tang-Du Hospital
Phase 1
30
Xi'an
2026-05-01
Not yet open
Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer
NCT07538193Carcinoma, Non-Small-Cell Lung (NSCLC), Neoplasm Staging, Lymphatic Metastasis
Tang-Du Hospital
Not applicable
28
Xi'an
2026-05
Recruiting
Intra-arterial Methylprednisolone After Endovascular Thrombectomy
NCT07516522Ischemia Stroke, Thrombectomy, Large Vessel Occlusion
Tang-Du Hospital
Phase 2
210
Xi'an
2026-03-31
Recruiting
Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)
NCT07354061NSCLC (Non-small Cell Lung Cancer)
Tang-Du Hospital
Phase 1/2
20
Xi’an
2026-03-25
Recruiting
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
NCT07385001Esophageal Squamous Cell Carcinoma, Ivonescimab, Neoadjuvant
Tang-Du Hospital
Phase 1/2
45
Xi'an
2026-01-28
Recruiting
Efficacy and Safety of Fully Resorbable Sinus Drug-eluting Stents in Patients With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps After Surgery: A Prospective, Randomized Controlled Trial
NCT07498374Eosinophilic Chronic Rhinosinusitis With Nasal Polyps
Tang-Du Hospital
Not applicable
192
Xi'an
2026-01-21
Recruiting
Safety and Efficacy Analysis of Stent-assisted Coil Embolization in the Treatment of Acute Ruptured Intracranial Aneurysms in the Perioperative Period.
NCT07683377Ruptured Aneurysm of Intracranial Artery, Stent-Assisted Coiling, Efficacy and Safety
Tang-Du Hospital
Not applicable
174
Xi'an
2026-01-01
Recruiting
Anxiety and Depression in IBS: A Brain-Gut Axis Study
NCT07646834Irritable Bowel Syndrome (IBS), Anxiety, Depression
Tang-Du Hospital
Observational
200
Xi'an
2025-12-21
Recruiting
Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)
NCT07377305NMO Spectrum Disorder
Tang-Du Hospital
Not applicable
12
Xi'an
2025-12-08
Recruiting
Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
NCT07494877Infertility
Tang-Du Hospital
Observational
300
Xi'an
2025-09-01
Recruiting
Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy
NCT07141264SCLC,Extensive Stage
Tang-Du Hospital
Phase 2
32
Xi'an
2025-08-25
Recruiting
Intra-arterial Methylprednisolone After Successful Endovascular Thrombectomy Anterior Circulation Large Vessel Occlusion
NCT07141303Acute Ischemic Stroke
Tang-Du Hospital
Phase 3
1,060
Xi'an
2025-08-08
Recruiting
Effect of Semi-elemental Enteral Nutrition on Gastrointestinal Tolerance in Patients With Traumatic Brain Injury.
NCT07092423Traumatic Brain Injury, Neurocritical Care, Enteral Feeding Intolerance
Tang-Du Hospital
Not applicable
100
Xi'an
2025-05-18
Not yet open
Clinical Trial on the Efficacy and Safety of Biodegradable 3D-Printed Implants in Chest Wall Reconstruction Surgery
NCT06977022Chest Wall Tumor
Tang-Du Hospital
Not applicable
20
Xi'an
2025-05
Recruiting
Evaluating Mechanically Engineered Stem Cell Exosomes for Treating Endometrial Injury: A Clinical Study
NCT06896747Thin Endometrial Lining, Female Infertility, Intrauterine Adhesions
Tang-Du Hospital
Phase 1/2
90
Xi'an
2025-02-21
Recruiting
Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC
NCT06864624NSCLC
Tang-Du Hospital
Phase 2
27
Changsha, Yinchuan, Xi'an
2025-02-18
Recruiting
Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study
NCT06663059Esophageal Cancer
Tang-Du Hospital
Phase 2
80
Xi'an
2024-10-01
Recruiting
Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
NCT06128252Gastric Cancer
Tang-Du Hospital
Not applicable
96
Wuhan, Nanjing, Shenyang, Xi'an, Chengdu, Ürümqi, Chongqing, Shanghai
2024-09-01
Recruiting
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial
NCT06485544Small Cell Lung Cancer (SCLC)
Tang-Du Hospital
Phase 2
104
Xi'an
2024-07-01
Not yet open
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
NCT06475755Non-Small Cell Lung Cancer, Anti Angiogenesis
Tang-Du Hospital
Phase 2
178
Xi'an
2024-06-30
Recruiting
Adebrelimab + Apatinib in SCLC Maintenance Therapy
NCT06475209SCLC
Tang-Du Hospital
Phase 2
60
Xi'an
2024-06-20
Recruiting
Partial Pressure of Oxygen Control Method in Identification of Intersegmental Plane
NCT06644066Lung Cancer
Tang-Du Hospital
Not applicable
60
Xi'an
2024-05-01
Recruiting
Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
NCT06467786Small Cell Lung Cancer
Tang-Du Hospital
Phase 4
24
Xi'an
2024-03-15
Recruiting
Baricitinib for Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions
NCT06065046Traumatic Brain Injury
Tang-Du Hospital
Phase 2
100
Xi'an
2023-11-24
Recruiting
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC
NCT06055738Locally Advanced Cervical Cancer
Tang-Du Hospital
Phase 2
20
Xi'an
2023-10-09
Active, closed
fMRI Study of the Neural Mechanism of rTMS in the Treatment of Nicotine Dependence
NCT06762535Tobacco Use Disorder, Repetitive Transcranial Magnetic Stimulation
Tang-Du Hospital
Not applicable
50
Xi'an
2023-04-01
Recruiting
Clinical Value of Saline Infusion Sonohysterography in the Assessment of Cesarean Scar Defects
NCT07610668Infertility
Tang-Du Hospital
Observational
300
Xi'an
2023-01-01
Active, closed
Rituximab for the Treatment of New-onset AChR-Myasthenia Gravis
NCT07071246Treatment
Tang-Du Hospital
Not applicable
30
Xi'an
2022-08-01
Recruiting
Neoadjuvant Therapy for Stage II-IVA Resectable Esophageal Squamous Cell
NCT06006650Neoadjuvent, PD-1 Inhibitor, Chemotherapy, Esophageal Squamous Cell Carcinoma
Tang-Du Hospital
Phase 2
114
Xi'an, Xi’an
2022-08-01
Recruiting
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
NCT05067348Myasthenia Gravis, Generalized
Tang-Du Hospital
Phase 2
64
Beijing, Changsha, Xi'an, Shanghai, Chengdu, Tianjin
2022-07-21
Recruiting
Ofatumumab in AQP4-IgG Seropositive NMOSD
NCT05504694Neuromyelitis Optica Spectrum Disorder
Tang-Du Hospital
Phase 1/2
5
Xi'an
2022-06-28
Recruiting
Assessment of Brain Cognitive Impairment in Breast Cancer
NCT05305092Breast Cancer, Chemo-brain, Endocrine Therapy
Tang-Du Hospital
Observational
90
Xi'an
2022-05-31
Active, closed
Neoadjuvant Furmonertinib and Cisplatin/Pemetrexed as in EGFR Mutated Stage IIA-IIIB Resectable NSCLC (FORESEE)
NCT05430802Non-small Cell Lung Cancer
Tang-Du Hospital
Phase 2
40
Xi'an
2022-02-24
Not yet open
Exosome-based Nanoplatform for Ldlr mRNA Delivery in FH
NCT05043181Familial Hypercholesterolemia
Tang-Du Hospital
Phase 1
30
Xi'an
2021-12
Active, closed
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
NCT05400070Sintilimab, Lung Cancer, Anlotinib, Chemotherapy
Tang-Du Hospital
Phase 2
45
Xi'an
2021-03-01
Recruiting
Assess the Risk of Cerebrovascular Disease
NCT04443439Cerebrovascular Disease
Tang-Du Hospital
Observational
100
Xi'an
2020-10-09
Recruiting
TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
NCT04182984Ocular Myasthenia Gravis
Tang-Du Hospital
Observational
200
Xi'an
2019-11-04
Recruiting
The Early Warning System for the Diabetic Encephalopathy
NCT02420470Diabetes Mellitus Type 2, Mild Cognitive Impairment, Metabolic Syndrome X
Tang-Du Hospital
Observational
300
Xi'an
2015-04
Rows per page Showing 1–49 of 49
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/xi-an

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 49 of those studies with a site in Xi’an that also match the filters currently applied.

How many clinical trials are recruiting in Xi’an?

32 of the 49 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 12 have not yet opened recruitment, 4 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Xi’an), 49 studies
PhaseStudiesRecruitingShare
Phase 2181236.7%
Not applicable12724.5%
Observational9718.4%
Phase 1/2448.2%
Phase 1204.1%
Phase 3214.1%
Phase 4214.1%

Most active sponsors

Lead sponsors with the most studies (Xi’an)
Lead sponsorStudiesRecruiting
Tang-Du Hospital4932
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.